Q-omics provides the consensus-scored SMIM23 profile across patient tissues and cancer cell-line models. SMIM23 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SMIM23 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SMIM23 RNA expression shows 6,769 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, KIRC, and STAD as cancer lineages where SMIM23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM23 survival associations across molecular data types. SMIM23 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM23 RNA expression–survival associations across cancer types. High SMIM23 expression shows unfavorable associations in THCA, KIRP, LUSC, KIRC and KICH, but favorable associations in BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for SMIM23 RNA expression.
This table summarizes SMIM23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM23 shows lower tumor expression in PAAD and higher tumor expression in KIRC, BRCA, LUAD, CHOL and UCEC. The KIRC box plot shows higher SMIM23 RNA expression in tumor versus normal tissue (log2 FC = +0.099, t-test p < 0.001).
This table shows molecular features associated with SMIM23 in patient tissues and cancer cell lines. In patient samples, SMIM23 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
